Silly. You are not a neurosurgeon, and Dr. Liau is, and must make recommendations to compassionate care cases based upon her best up to date knowledge. Her studies, interviews and conference presentations still show her leaning toward not typically steering idh mutant type tumor patients toward DC therapy.
There is no such thing as secondary GBM anymore.
No one has stated that a patient would be denied DCVax-l (if approved) if they are suffering from something other than GBM, but it is less likely they’d be directed toward it without additional study data. There is a decision making tree most neurooncologists follow, with room for patient doctor decisions to try something else.
You’ll have to wait and see the results for the current trial — like everyone else.
News 
Market Data 
Discover 
